Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial
Abstract
Hypnotic medications can adversely affect behavior during unanticipated awakenings during the night. Animals treated with the hypocretin (Hcrt) receptor antagonist almorexant (ALM) have less acute cognitive impairment compared to the GABAA receptor modulator zolpidem (ZOL). This study aimed to determine whether ALM produces less acute cognitive impairment than ZOL in human subjects.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 18, 2020
- Source ID
- 10.1093/sleep/zsaa080
Entities
People
- Anne Richards
- Aoife O'donovan
- Jennifer Hlavin
- Jonathan Varbel
- Kristin Samuelson
- Leslie M Ruoff
- Melinda Sivasubramanian
- Sabra S. Inslicht
- Stephen R Morairty
- Steven L. Batki
- Terri Motraghi
- Thomas C. Neylan
- Thomas J. Metzler
- Thomas Kilduff
Organizations
- National Center for Advancing Translational Sciences
- National Institutes of Health
- SRI International
- San Francisco VA Medical Center
- United States Army Medical Research and Development Command
- University of California, San Francisco
- University of Colorado